Print
Email
Print Edition Stories
MHT's Julie Donnelly: Biotechs lag in social media use
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
AVEO Pharmaceuticals has presented results on a pair of cancer treatments at the Symposium of the European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research in Berlin, Germany.
The Cambridge-based company (Nasdaq: AVEO) issued separate press releases on the two announcements.
AVEO said that its Tivozanib, working in combination with FOLFOX6, demonstrated anti-tumor activity in advanced gastro-intestinal cancers in a Phase 1b clinical trial. Tivozanib is designed to be a potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen for patients with advanced GI cancers. AVEO said the results show partial responses in 35 percent of patients evaluated and disease control in 82 percent of patients. The company also said the combination was considered safe in the Phase 1b clinical trial at the full recommended tivozanib dose.
In addition, the company evaluated presented data on a pre-clinical study of tivozanib and capecitabine, 5-fluorouracil (5-FU) and docetaxel, as single agents and in combination, in genetically engineered HER2 driven as well as traditional breast tumor models. According to AVEO, the data demonstrates that addition of capecitabine to tivozanib in a tivozanib resistant HER2 driven breast tumor model led to complete tumor growth inhibition.
In a separate announcement, AVEO said that preclinical data from its anti-RON (Recepteur d’Origine Nanatais, or MST1R) antibody program, which identified antibodies with potent anti-tumor activity that demonstrated inhibition of the function of both wild type RON and the RON160 variant, as well as a potential biomarker to identify tumors likely to respond to treatment with the anti-RON antibody.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
